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We  evaluated the possible association between FCGR3A V/F (158) polymorphism and SLE sus-
ceptibility and clinical phenotype in 305 sequentially retrieved SLE patients and 300 healthy
controls from the southeastern part of Brazil by allele-speciﬁc polymerase chain reaction.
Our  results showed no association between FCGR3A 158V/F alleles and susceptibility to SLE
in  this series of patients albeit the heterozygous genotype was strongly associated with the
disease.
©  2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Polimorﬁsmo  do  receptor  Fc  gama  IIIa  não  está  associado  à
susceptibilidade  ao  lúpus  eritematoso  sistêmico  em  pacientes  brasileiros
alavras-chave:
úpus eritematoso sistêmico
eceptor Fc gama IIIa
r  e  s  u  m  o
Avaliou-se a possível associac¸ão entre o polimorﬁsmo FCGR3A V/F (158) e a suscetibilidade
e  o fenótipo clínico do lúpus eritematoso sistêmico (LES) em 305 pacientes com LES admi-
tidos sequencialmente e 300 controles saudáveis da Região Sudeste do Brasil por reac¸ão
olimorﬁsmo de nucleotídeo único
olimorﬁsmo genético
munogenética
em  cadeia da polimerase alelo-especíﬁca. Os resultados do presente estudo mostraram não
haver associac¸ão entre os alelos FCGR3A 158V/F e a suscetibilidade ao LES nessa série de
pacientes, ainda que o genótipo heterozigoto tenha sido fortemente associado à doenc¸a.
© 2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  CClicen∗ Corresponding author.
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Introduction
Systemic lupus erythematosus (SLE) is considered the pro-
totype of chronic immune complex-mediated diseases. In
physiological conditions, circulating immune complexes (IC)
are removed from the peripheral blood and other biological
ﬂuids by the mononuclear phagocytic system.1,2 In SLE, the
inadequate clearance of IC may lead to tissue damage due to
IC tissue deposition and overload, which results in release of
inﬂammatory mediators and inﬂammatory cell inﬂux.2,3 The
Fc gamma receptors (FcR), present in mononuclear phago-
cytic cells, play an important role in the clearance of IC and
apoptotic cells.4,5 In addition, the internalization of nucleic
acid-containing IC via FcR  by plasmacytoid dendritic cells
allows the binding of intracellular toll-like receptors (TLR) and
consequent activation of downstream cascades that culmi-
nate in the synthesis of type I interferon.6,7 Several single
nucleotide polymorphisms (SNPs) have been described in the
FcR encoding genes, and some of them have functional con-
sequences. As expected, some of these polymorphisms have
been extensively studied in autoimmune diseases.5,8
Human FcRIII (CD16) receptor is an extensively glyco-
sylated heterogeneous protein with an apparent molecular
weight of 50–80 kDa. FCGR3A gene codes for the FcRIIIa
receptor present in macrophages, NK and  T cells, with low-
afﬁnity for IgG-containing IC.4,9,10 The FCGR3A gene presents
a G559T polymorphism that leads to the substitution of
Valine for Phenylalanine at position 158 of the polypeptide
chain (158V/F), reducing even more  the receptor afﬁnity for
IgG subclasses.9–11 The association between FCGR3A gene
polymorphism and SLE has been studied by several inves-
tigators. However, conﬂicting results have been reported
concerning this association in different populations.9,10,12–16
Given this scenario, the present study aimed at investi-
gating the FcRIIIa 158V/F polymorphism in Brazilian SLE
patients that are embedded in a population with mixed ethnic
background.
Material  and  methods
Patients  and  controls
Peripheral blood was obtained from 305 sequentially retrieved
SLE patients attending the Rheumatology Outpatient Clinic
at Universidade Federal de São Paulo – UNIFESP, Brazil.
All patients met  at least four of the revised criteria for
classiﬁcation of SLE according to the American College of
Rheumatology.17 Detailed clinical characteristics were not
available for all patients and only the charts with consistent
data were considered in the analysis of the clinical phenotype
of disease. Accordingly, Systemic Lupus International Collab-
orating Clinics/American College of Rheumatology-Damage
Index (SLICC-DI) data was available for 167 patients. The
control group comprised 300 healthy blood donors who had
no family history of autoimmune diseases as assessed by a
detailed questionnaire. The study was approved by the Insti-
tutional Ethics Committee (# 2074/07) and all participants
provided written informed consent. 0 1 6;5 6(6):515–520
Ethnic  classiﬁcation
Latin American countries in general, and Brazil in particular,
present intense ethnic miscegenation, mainly at the expense
of African and European elements. We  adopted the ethnic
classiﬁcation used by the Grupo Latinoamericano de Estudio
del Lupus (GLADEL).18 According to this classiﬁcation, the indi-
vidual sorts himself regarding his own ethnicity as well as
his parents and four grandparents. The ethnic groups studied
were deﬁned as follows:
) Black ethnicity: individual in the study, parents and grand-
parents classiﬁed as black.
) White ethnicity: individual in the study, parents and grand-
parents classiﬁed as white.
c) Mixed ethnicity: existence of at least one disagreement in
the lineage of the individual classiﬁcation by maternal or
paternal grandparents.
Nucleic  acid  isolation  and  FCGR3A  polymorphism  analysis
Genomic DNA was extracted from blood samples by salting
out, based on the methodology previously described by Laiti-
nen et al.19 We examined the single nucleotide polymorphism
(SNP)G559T (rs396991) of FCGR3A (http://www.ncbi.nlm.
nih.gov/gene/2214) by allele-speciﬁc PCR according to Wu
et al.9 with minor modiﬁcations, using a single sense primer
(5′ TCA CAT ATT TAC AGA ATG GCA ATG G 3′) and two  anti-
sense primers: 5′ TCT CTG AAG ACA CAT TTC TAC TCC CTA
C 3′ for G allele; and 5′ TCT CTG AAG ACA CAT TTC TAC TCC
CTA A 3′) for T allele. The 50 L reaction mixture contained
100 ng DNA, 1.2 mM MgCl2, 0.2 m MdNTP, 2.5 U Platinum Taq
DNA Polymerase and 10 pmol of each allele-speciﬁc sense and
antisense primers. PCR started with an initial step of 5 min  at
95 ◦C, followed by 35 cycles of 30 s at 94 ◦C, 45 s at 54 ◦C, and 20 s
at 72 ◦C, with a ﬁnal extension step of 8 min  at 72 ◦C. The 138 bp
amplicon was analyzed by electrophoresis on a 3% agarose gel
in TBE.
Research  for  autoantibodies
We identiﬁed all subserologies (double-stranded DNA, Sm,
RNP, SSA, SSB). We used indirect immunoﬂuorescence for ANA
test and ds-DNA and Ouchterlony double diffusion for the
autoantibodies Sm,  RNP, SSA-Ro and SSB-La.
Statistical  analysis
Chi-square test and the Bonferroni correction for multi-
ple comparisons were used to analyze categorical variables,
and the Fisher’s exact test was employed when appropri-
ate. Continuous variables were tested for the pattern of
distribution by the Kolmogorov–Smirnoff test. Variables with
normal distribution were analyzed by the Student’s t test, andKruskal–Wallis test (three or more  groups) followed by the
Mann–Whitney test. Signiﬁcance was established at p < 0.05.
Statistical calculations were performed with SPSS 17.0 and
Minitab Statistical 15.0.
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Table 1 – Ethnic and gender distribution of SLE patients and controls.
SLE Controls
Ethnicity n % n % pa
Black 12 3.9 16  5.4 0.113
White 111 36.4 130  43.3
Mixed 182 59.7 154 51.3
Gender Female Male Female Male pa
291 14 178 122 <0.001
a Chi-square test.
Table 2 – FCGR3A genotype and allele distribution in SLE patients and controls.
SLE Controls
Genotype n % n % pa pb
VV 35 11.5 54 18.0 0.002 0.023
FF 23 7.5 39 13.0 0.027
VF 247 81.0 207 69.0 <0.001
Allele n % n % pc
V 317 52.0 315 52.5 0.853
F 293 48.0 285 47.5
a Chi-square test.
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Fig. 1 – Boxplot distribution of SLICC/ACR-DI according to
the FCGR3A genotypes. No association was found between
the damage score and any particular FCGR3A genotypeb Bonferroni correction for multiple comparisons method.
c Chi-square test.
esults
here was no difference between patients and controls
egarding ethnic background distribution, but the SLE group
ad a lower frequency of males as compared to the control
roup (Table 1). However, the statistical analysis performed
ithin each group conﬁrmed that neither allele distribution
SLE patients p = 0.863; controls p = 1.000) nor genotype distri-
ution (SLE patients p = 0.449; controls p = 1.000), was gender
elated (data not shown).
The patient group had a signiﬁcantly higher proportion
f heterozygous individuals (VF) than the control group
Table 2). Accordingly, the control group presented a sig-
iﬁcantly higher proportion of the homozygous FCGR3A
enotypes VV (p = 0.023) and FF (p = 0.027). As expected,
here was no difference between groups regarding the
revalence of individual alleles (p = 0.853) (Table 2). The
CGR3A genotype distribution showed deviation from the
ardy Weinberg equilibrium in both, SLE and control
roups.
There was no association between most clinical mani-
estations and genotypes (Table 3) with the exception of a
igher frequency of central nervous system (CNS) manifes-
ations, observed in patients with FCGR3A VV genotype (5
atients had psychosis, three had convulsions and one had
ther manifestation). Among the 167 SLE patients with avail-
ble SLICC/ACR-DI records, no association was found between
his damage score and any FCGR3A genotype (p = 0.300) (Fig. 1).
o association was found between FCGR3A genotypes and
he presence of the individual autoantibodies anti-dsDNA,(p = 0.300).
anti-Sm, anti-RNP, anti-SS-A/Ro and anti-SS-B/La among the
305 SLE patients (Table 4).
DiscussionThis is the ﬁrst study analyzing FCGR3A polymorphism
in Brazilian SLE patients. Despite the sizable number of
patients and normal controls, no difference was found in the
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Table 3 – Clinical manifestations of SLE patients according to FCGR3A genotype.
Manifestation (n) VV  FF VF pa
n % n % n %
Skin (178) ⊕  16 100.0 6  100.0 147 94.0 0.511
∅ 0 0.0 0  0.0 9 6.0
Oral ulcers (145) ⊕  1 6.7 0 0.0 28 22.6 0.158
∅ 14 93.3 6 100.0 96 77.4
Arthritis (178) ⊕  16 100.0 6 100.0 138 88.5 0.244
∅ 0 0.0 0 0.0 18 11.5
Hematologic (178) ⊕ 10 62.5 5 83.3 116 74.3 0.509
∅ 6 37.5 1 16.7 40 25.7
Renal (178) ⊕  10 62.5 2 33.3 88 56.4 0.463
∅ 6 37.5 4 66.7 68 43.6
Serositis (178) ⊕  4 25.0 1 16.7 38 24.3 0.909
∅ 12 75.0 5 83.3 118 75.7
CNS (177) ⊕  9 53.3 1 17.7 30 19.4 0.003
∅ 7 43.8 5 83.3 125 80.6
n, number of patients with consistent records for each clinical trait; CNS, c
a Chi-square test.
Table 4 – Presence of individual autoantibodies in SLE
patients according to the FCGR3A genotype.
Autoantibody Genotype pa
VV (n = 35) FF (n = 23) VF (n = 247)
+ % + % + %
Anti-dsDNA 12 34.3 8 34.8 72 29.1 0.832
Anti-Sm 8 22.9 6 26.1 37 15.0 0.231
Anti-RNP 15 42.9 8 34.8 73 29.6 0.267
Anti-SS-A/Ro 8 22.9 10 43.5 74 30.0 0.243
Anti-SS-B/La 0 0 3 13.0 25 10.1 0.122a Chi-square test.
distribution of FCGR3A 158V/F alleles between SLE and healthy
controls. Interestingly, SLE patients did show a signiﬁcantly
higher frequency of the heterozygous 158V/F genotype. In
addition, there was a higher frequency of the VV homozy-
gous genotype in patients with a history of CNS involvement.
Other clinical traits and disease severity were not associated
with FCGR3A polymorphism in this series. According to our
results, the FCGR3A genotype distribution did not obey the
Hardy Weinberg equilibrium. One possible explanation for this
observation is the existence of gene copy number variation, a
major cause of deviation of Hardy–Weinberg equilibrium.20 In
fact, recent studies have shown that Fc  receptor genes may
present copy number variation, including FCGR3A, FCGR3B,
and FCGR2C genes.21,22
Willcocks and colleagues found an association between low
FCGR3B gene copy number and SLE in Caucasians, however
this association was not seen in Chinese SLE patients in gen-
eral or when SLE patients with lupus nephritis were analyzed
separately.23 In another study with the Chinese population,
Zhou and colleagues found an association between increased
FCGR3A gene copy number (3 or 4) and the presence of anti-
24glomerular basement membrane antibody.
It is known that the FCGR3A 158V allele encodes for a higher
afﬁnity receptor than the 158F allele.9,10 Consistent with the
role played by FcRIIIa in immune complex clearance, it isentral nervous system; ⊕, presence genotype; ∅, absence genotype.
conceivable that the decreased binding capacity of the 158F
allele would be associated with immune complex-mediated
diseases. In fact, an increased susceptibility to SLE in FCGR3A
158F/F individuals has been reported in some ethnic groups.3
However, the literature is controversial regarding this asso-
ciation. Among Japanese, homozygosis for the 158F allele
contributed to SLE susceptibility,15 but in the Thai popula-
tion, only a tendency to association was found between the FF
genotype and SLE susceptibility.25 No association was found
between the 158V/F polymorphism and SLE in Spanish,14
African-American,12 and Mexican individuals.11 In Koreans,
according to Salmon et al.,26 homozygosis for the F allele
constituted a risk factor for lupus nephritis, in contrast to
the results of Lee and colleagues, who found no association
between this polymorphism and SLE in this ethnic group.27 In
the German population, although the FcRIIIa polymorphism
did not confer susceptibility to SLE, the presence of the F allele
was associated with clinical manifestations, prognosis, and
course of disease (Table 5).1
In our study the heterozygous genotype (VF) was more
prevalent in SLE patients, and as expected this caused no dif-
ference in the allelic distribution between SLE and control
groups. The reason for a higher frequency of the heterozy-
gous 158V/F genotype in SLE patients is not readily clear.
It could be related to copy number variation and it may be
hypothesized that an intermediate afﬁnity state in the pool
of FcRIIIa receptors, as provided by the coexistence of high
avidity (158V) and low avidity (158F) FCGR3A variants, would
set an immune complex-clearance scenario favorable to the
development of immune complex-mediated diseases in this
ethnic set-up. Experimental data are required to test this
hypothesis.
Another important aspect to be considered is that the
isolated analysis of FCGR3A polymorphism may be an over-
simpliﬁcation of the problem. It should be remembered that
FcRIIIa is one of several receptors involved in immune
complex clearance. Therefore, the ﬁnal immune complex
clearance capacity should correspond to the overall genetic
make-up of the several receptors involved in this process.
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Table 5 – FCGR3A-158V/F polymorphism and SLE in various ethnic groups.
Ethnicity Patients (n) Increased
susceptibility
Genotypic
association
Phenotype  association Ref Year publication
Clinical trait pa
Korean 148 No 158 F/F Nephritis <0.007 20 1999
African-American 77 No ND No ND 12 1999
Japanese 193 Yes 158 F/F Nephritis 0.03 15 2002
Spanish 276 No ND No ND 14 2002
Korean 145 No ND No ND 21 2002
German 140 No ND No ND 1 2002
Thai 87 Trend 158 F/F Malar rash 0.03 19 2003
Trend Discoid rash 0.04
Mexican 94 No ND No ND 11 2011
ND, not determined.
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With respect to SLE clinical manifestations, Wu and col-
eagues found that there was a strong association between the
F genotype and lupus nephritis in Americans from diverse
enetic background,9 similarly to what was observed in the
orean population by Salmon et al., in 1999.26 However, even
n Americans with varied genetic background the role of
CGR3A polymorphism in SLE phenotype is not clear, since
larcon and colleagues found that homozygosis for the V
llele (FCGR3A*GG) was a signiﬁcant predictor of end-stage
enal disease among SLE patients with kidney disease.28 The
ssociation of the 158 F allele with lupus nephritis9,26 and
he association of the V allele with end-stage renal disease28
uggest that other still unknown factors may inﬂuence the
evelopment and outcome of renal manifestations in SLE.
ssociation between the VV genotype and history of CNS
nvolvement has not been reported by other authors. This orig-
nal ﬁnding is intriguing, but one should keep in mind that,
ue to the low number of homozygous VV SLE patients in the
resent series, this association must be regarded as prelimi-
ary.
In conclusion, this original analysis of FCGR3A 158V/F
olymorphism in Brazilian SLE patients showed no associ-
tion between any of the alleles and susceptibility to SLE,
ut disclosed a remarkably higher frequency of the het-
rozygous 158V/F genotype in SLE patients as compared to
ealthy controls. In addition, we  have not conﬁrmed the pre-
iously reported association between the 158 F allele and lupus
ephritis in our series, but we  did ﬁnd an intriguing asso-
iation between the 158V allele and central nervous system
nvolvement. The present ﬁndings support the impact of the
enetic variability of the Fc  receptors in general and the
cRIIIa in particular on the susceptibility and phenotype of
ystemic lupus erythematosus. Our preliminary results war-
ant further studies to conﬁrm and investigate the role of the
amily of Fc  receptors in the pathophysiology of systemic
upus erythematosus.unding
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